Paris (France) and Cambridge (Massachusetts, USA), February 27, 2026 – Biophytis SA (Euronext Growth Paris: ALBPS), (“the Company”), a pioneering company in the development of transformative therapies impacting longevity, announces several amendments to its bond financing initially announced on August 5, 2025, in mutual agreement with Hexagon Capital Fund.
Biophytis strengthens its financial position and extends its cash runway into Q1 2027
Cash position strengthened to €3.0 million Most 2026 share warrants exercised Phase 2 study in obesity to start in Q1 2027 Hong-Kong JV to start operations for preparing Phase 3…
